Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen

RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well donor umbilical cord blood transplant with reduced intensity conditioning works in treating patients with advanced hematological cancer or other disease.

Study Overview

• Status: Terminated
• Conditions: Lymphoma; Myelodysplastic Syndromes; Leukemia; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic/Myeloproliferative Diseases
• Intervention / Treatment: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total body irradiation; Biological: anti-thymocyte globulin

Detailed Description

OBJECTIVES:

Primary

• To estimate the probability of survival at 1 year in patients with advanced hematological malignancies or other diseases treated with non-myeloablative unrelated donor umbilical cord blood transplantation.

Secondary

• Six month non-relapse mortality.
• Chimerism at days 7, 14, 21, 28, 56, and 80, at 6 months, and at 1 and 2 years.
• To determine the incidence of neutrophil engraftment at day 42.
• To determine the incidence of platelet engraftment at 6 months.
• To determine the incidence of grade II-IV and III-IV acute graft-versus-host-disease (GVHD) at day 100.
• To determine the incidence of chronic GVHD at 1 year.
• To determine the incidence of clinically significant infections at 6 months and at 1 and 2 years.
• To determine the probability of progression-free survival at 1 and 2 years.
• To determine the probability of survival at 2 years.
• To determine the incidence of relapse or disease progression at 1 and 2 years.

OUTLINE: Patients are stratified according to disease status and prior therapy (hematologic malignancy or other disease that was treated with an autologous stem cell transplant or ≥ 2 courses of multiagent chemotherapy within the past 3 months vs hematologic malignancy or other disease that was treated with an autologous stem cell transplant > 12 months ago or with ≤ 1 course of multiagent chemotherapy or immunosuppressive chemotherapy within the past 3 months vs refractory leukemia or lymphoma for which patient was rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy).

• Conditioning regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV on day -6. Patients also undergo total body irradiation on day -1. Some patients also receive anti-thymocyte globulin IV on days -6 to -4.
• Umbilical cord blood transplantation (UCBT): Patients undergo UCBT on day 0.
• Immunosuppressive therapy (graft-versus-host disease prophylaxis): Patients receive cyclosporine IV over 1 hour or orally (as tolerated) every 8 or 12 hours beginning on day -3 and continuing for approximately 6 months. Patients also receive mycophenolate mofetil IV every 8 hours on days -3 to 5 and then orally on days 6-30.

After completion of study treatment, patients are followed at 6 months and then annually thereafter.

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Washington
    • Seattle, Washington, United States, 98109
      • Fred Hutchinson Cancer Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 69 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Diagnosis of advanced hematologic malignancy or other disease not curable by conventional chemotherapy, including any of the following:

  • Acute myeloid leukemia in complete remission (CR)* (as defined by hematologic recovery, < 5% blasts in the bone marrow by morphology, and a cellularity of > 15%), meeting one of the following criteria:

    • In first complete remission (CR1) AND has high-risk disease as evidenced by any of the following:

      • Preceding myelodysplastic syndromes (MDS)
      • High-risk cytogenetics (e.g., monosomy 5 or 7, or as defined by referring institution treatment protocol)
      • Required > 2 courses of therapy to obtain CR
      • Erythroblastic or megakaryocytic leukemia
    • In second CR (CR2) or beyond

  • Acute lymphoblastic leukemia in CR* (as defined by hematologic recovery, < 5% blasts in the bone marrow by morphology, and a cellularity of > 15%), meeting one of the following criteria:

    • In CR1 AND has high-risk disease as evidenced by any of the following:

      • t(9;22), t(1;19), t(4;11), or other MLL rearrangements
      • Hyplodiploid
      • Required > 1 course of therapy to obtain CR
    • Beyond CR2

  • Chronic myelogenous leukemia (CML)

    • All types are allowed (except refractory blast crisis CML)
    • Patients in chronic phase CML must have failed or been intolerant to prior imatinib mesylate (Gleevec) or other tyrosine kinase inhibitors

  • MDS

    • Any subtype allowed (including refractory anemia [RA])
    • Severe pancytopenia or complex cytogenetics
    • Blasts must be < 5% (if blasts are ≥ 5%, pre-transplant induction therapy is required to reduce blast count to < 5%)

  • Large cell lymphoma, Hodgkin lymphoma, or multiple myeloma, meeting one of the following criteria:

    • Chemotherapy-sensitive disease that has failed prior therapy

      • Patients with large cell lymphoma or Hodgkin lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky)
    • Ineligible for an autologous stem cell transplant

  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, or follicular lymphoma that has progressed after ≥ 2 prior therapies

    • Patients with bulky disease should be considered for debulking chemotherapy prior to transplant
    • Patients with refractory disease are eligible provided disease is non-bulky AND an estimated tumor doubling time is ≥ 1 month

  • Lymphoplasmacytic lymphoma, mantle cell lymphoma, or prolymphocytic leukemia

    • Chemotherapy-sensitive disease that was previously treated with initial therapy

      • Patients with mantle cell lymphoma must not have progressive disease during salvage therapy (stable disease allowed provided it is non-bulky)
  • Mycosis fungoides and Sezary syndrome
  • Bone marrow failure syndromes, except for Fanconi anemia
  • Myeloproliferative syndromes NOTE: *Patients for whom adequate marrow/biopsy specimens can not be obtained to determine remission status by morphologic assessment must have fulfilled criteria of remission (< 5% blasts by flow cytometry and recovery of peripheral blood counts with no circulating blasts)

• Ineligible for autologous stem cell transplant due to any of the following:

  • Prior autologous stem cell transplant
  • Inadequate autologous stem cell harvest
  • Inability to withstand a myeloablative preparative regimen
  • Clinically aggressive/high-risk disease
• No evidence of progressive disease by imaging modalities or biopsy (persistent PET scan activity allowed provided there are no CT scan changes indicating progression)
• Acute leukemia that is refractory, persistent, or relapsed (defined as > 5% blasts in normocellular bone marrow) allowed provided patient was rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy
• Patients with stable disease are eligible provided the largest residual nodal mass is approximately < 5 cm (largest residual mass must represent a 50% reduction and be approximately < 7.5 cm for patients who have responded to prior therapy)
• No active CNS malignancy

• Umbilical cord blood (UCB) donor available

  • UCB graft matched at 4/6 HLA-A, -B, and -DRB1 antigens with the recipient

    • May include 0-2 antigen mismatches at the A, B, or DRB1 loci
    • Unit selection based on cryopreserved nucleated cell dose and HLA-A, -B, and -DRB1 using intermediate resolution A, B antigen and DRB1 allele typing
  • If 2 UCB units are required to reach the target cell dose, each unit must be a 3/6 HLA-A, -B, and -DRB1 antigen match to each other, as well as a 4/6 antigen match to the recipient
  • No 5-6/6 HLA-A, -B, and -DRB1 matched sibling donor available

PATIENT CHARACTERISTICS:

• Karnofsky performance status (PS) 60-100% OR Lansky PS 50-100%

• Creatinine ≤ 2.0 mg/dL (adults) OR creatinine clearance > 40 mL/min (pediatrics)

  • Adult patients with a creatinine > 1.2 mg/dL or a history of renal dysfunction must have an estimated creatinine clearance of > 40 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• LVEF ≥ 35%
• DLCO > 30% predicted
• No requirement for O_2
• No decompensated congestive heart failure
• No uncontrolled arrhythmia

• None of the following liver diseases or conditions:

  • Fulminant liver failure
  • Cirrhosis with evidence of portal hypertension or bridging fibrosis
  • Alcoholic hepatitis
  • Esophageal varices
  • History of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction as evidenced by prolongation of the prothrombin time
  • Ascites related to portal hypertension
  • Bacterial or fungal abscess
  • Biliary obstruction
  • Chronic viral hepatitis with total serum bilirubin > 3 mg/dL
  • Symptomatic biliary disease
• Recent mold infection (e.g., Aspergillus) allowed provided patient received ≥ 30 days of appropriate treatment AND infection is controlled and cleared by Infectious Disease
• No evidence of HIV infection or known HIV-positive serology
• No uncontrolled viral or bacterial infection

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• At least 3 months since prior myeloablative stem cell transplantation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cyclophosphamide/Fludarabine/TBI; Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months. Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy.	Drug: cyclophosphamide; 50 mg/Kg Day -6; Drug: cyclosporine; Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.; Drug: fludarabine phosphate; 40mg/m2 Days -6 to -2; Drug: mycophenolate mofetil; 1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.; Procedure: umbilical cord blood transplantation; Single or double unit umbilical cord blood transplant; Radiation: total body irradiation; 200 cGy Day -1
Experimental: Cyclophosphamide/Fludarabine/TBI/ATG; Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months	Drug: cyclophosphamide; 50 mg/Kg Day -6; Drug: cyclosporine; Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.; Drug: fludarabine phosphate; 40mg/m2 Days -6 to -2; Drug: mycophenolate mofetil; 1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.; Procedure: umbilical cord blood transplantation; Single or double unit umbilical cord blood transplant; Radiation: total body irradiation; 200 cGy Day -1; Biological: anti-thymocyte globulin; 30mg/Kg Days -6 to -4

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Probability of Survival at 1 Year	Kaplan-Meier estimate of the probability of survival at 1 year	1 year post transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Probability of Survival at 2 Years	Kaplan-Meier estimate of the probability of survival at 2 years	2 years post transplant
Incidence of Non-relapse Mortality at 6 Months	Number of Participants with Non-relapse Mortality at 6 Months	6 months post transplant
Chimerism	Count of participants who experienced dominance of one cord blood unit (defined by >or= 95% contribution of one cord blood unit to BM and all PB fractions -- CD3+, CD33+, CD56+, and CD19+) at 7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant.	7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant
Incidence of Neutrophil Engraftment at Day 42	Number of participants with neutrophil engraftment at day 42	Day 42 post transplant
Incidence of Platelet Engraftment at 6 Months	Number of participants with platelet engraftment at 6 months	6 months post transplant
Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD) at Day 100	Number of participants with Grade II-IV acute graft-versus-host-disease (GVHD) at day 100. Acute GVHD Staging and Grading: Overall grade 1: stage 1-2 skin, no liver or gut Overall grade 2: stage 3 skin or stage 1 liver or stage 1 gut Overall grade 3: stage 4 skin or stage 2-4 liver or stage 2-4 gut (without GVHD as a major contributing cause of death) Overall grade 4: stage 4 skin or stage 2-4 liver or stage 2-3 gut (with GVHD as a major contributing cause of death)	Day 100 post transplant
Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD) at Day 100	Number of participants with Grade III-IV acute graft-versus-host-disease (GVHD) at day 100. Acute GVHD Staging and Grading: Overall grade 1: stage 1-2 skin, no liver or gut Overall grade 2: stage 3 skin or stage 1 liver or stage 1 gut Overall grade 3: stage 4 skin or stage 2-4 liver or stage 2-4 gut (without GVHD as a major contributing cause of death) Overall grade 4: stage 4 skin or stage 2-4 liver or stage 2-3 gut (with GVHD as a major contributing cause of death)	Day 100 post transplant
Incidence of Chronic Graft-versus-host-disease (GVHD) at 1 Year	Number of participants with chronic graft-versus-host-disease (GVHD) at 1 year. Clinical Limited cGVHD; Oral abnormalities consistent with cGVHD, a positive skin or lip biopsy, and no other manifestations of cGVHD.; Mild liver test abnormalities (alkaline phosphatase <2 x upper limit of normal, AST or ALT <3 x upper limit of normal and total bilirubin <1.6) with positive skin or lip biopsy, and no other manifestations of cGVHD.; Less than 6 papulosquamous plaques, macular-papular or lichenoid rash involving <20% of body surface area (BSA), dyspigmentation involving <20% BSA, or erythema involving <50% BSA, positive skin biopsy, and no other manifestations of cGVHD.; Ocular sicca (Schirmer's test <5mm with no more than minimal ocular symptoms), positive skin or lip biopsy, and no other manifestations of cGVHD.; Vaginal or vulvar abnormalities with positive biopsy, and no other manifestations of cGVHD.	1 year post transplant
Incidence of Clinically Significant Infections at 6 Months	Number of participants with clinically significant infections at 6 months	6 months post transplant
Incidence of Clinically Significant Infections at 1 Year	Number of participants with clinically significant infections at 1 year	1 year post transplant
Incidence of Clinically Significant Infections at 2 Years	Number of participants with clinically significant infections at 2 years	2 years post transplant
Probability of Progression-free Survival at 1 Year	Kaplan-Meier estimate of the probability of progression-free survival at 1 year	1 year post transplant
Probability of Progression-free Survival at 2 Years	Kaplan-Meier estimate of the probability of progression-free survival at 2 years	2 years post transplant
Incidence of Relapse at 1 Year	Number of participants with relapse at 1 year. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.	1 year post transplant
Incidence of Relapse at 2 Years	Number of participants with relapse at 2 years. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.	2 years post transplant

Collaborators and Investigators

• Sponsor: Fred Hutchinson Cancer Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Colleen Delaney, MD, MSC, Fred Hutchinson Cancer Center

Study record dates

Study Major Dates

• Study Start: November 1, 2005
• Primary Completion (Actual): November 1, 2008
• Study Completion (Actual): December 1, 2009

Study Registration Dates

• First Submitted: July 19, 2008
• First Submitted That Met QC Criteria: July 19, 2008
• First Posted (Estimate): July 22, 2008

Study Record Updates

• Last Update Posted (Actual): June 14, 2017
• Last Update Submitted That Met QC Criteria: May 19, 2017
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Keywords: stage III adult diffuse large cell lymphoma; stage III adult immunoblastic large cell lymphoma; stage IV grade 3 follicular lymphoma; stage IV adult diffuse large cell lymphoma; stage IV adult immunoblastic large cell lymphoma; recurrent grade 3 follicular lymphoma; recurrent adult diffuse large cell lymphoma; recurrent adult immunoblastic large cell lymphoma; stage IV childhood large cell lymphoma; recurrent childhood large cell lymphoma; refractory anemia; refractory anemia with ringed sideroblasts; refractory anemia with excess blasts; chronic myelomonocytic leukemia; de novo myelodysplastic syndromes; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes; juvenile myelomonocytic leukemia; childhood myelodysplastic syndromes; atypical chronic myeloid leukemia; recurrent adult Hodgkin lymphoma; childhood immunoblastic large cell lymphoma; recurrent/refractory childhood Hodgkin lymphoma; acute myeloid leukemia; Waldenstrom macroglobulinemia; stage III grade 1 follicular lymphoma; stage III grade 2 follicular lymphoma; stage III grade 3 follicular lymphoma; stage IV grade 1 follicular lymphoma; stage IV grade 2 follicular lymphoma; stage III mantle cell lymphoma; stage IV mantle cell lymphoma; stage II multiple myeloma; stage III multiple myeloma; recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; recurrent marginal zone lymphoma; recurrent small lymphocytic lymphoma; stage III small lymphocytic lymphoma; stage III marginal zone lymphoma; stage IV small lymphocytic lymphoma; stage IV marginal zone lymphoma; nodal marginal zone B-cell lymphoma; splenic marginal zone lymphoma; recurrent mantle cell lymphoma; stage III chronic lymphocytic leukemia; stage IV chronic lymphocytic leukemia; stage III adult Hodgkin lymphoma; stage IV adult Hodgkin lymphoma; anaplastic large cell lymphoma; stage III mycosis fungoides/Sezary syndrome; stage IV mycosis fungoides/Sezary syndrome; recurrent mycosis fungoides/Sezary syndrome; refractory multiple myeloma; polycythemia vera; essential thrombocythemia; stage III childhood large cell lymphoma; acute lymphoblastic leukemia; stage IV childhood Hodgkin lymphoma; chronic eosinophilic leukemia; chronic neutrophilic leukemia; stage III childhood Hodgkin lymphoma; chronic idiopathic myelofibrosis; childhood diffuse large cell lymphoma; recurrent childhood anaplastic large cell lymphoma; stage III childhood anaplastic large cell lymphoma; stage IV childhood anaplastic large cell lymphoma; refractory cytopenia with multilineage dysplasia; chronic myelogenous leukemia; myelodysplastic/myeloproliferative disease
• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Disease; Bone Marrow Diseases; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Precancerous Conditions; Lymphoma; Syndrome; Myelodysplastic Syndromes; Multiple Myeloma; Neoplasms, Plasma Cell; Leukemia; Preleukemia; Plasmacytoma; Myeloproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Dermatologic Agents; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Antitubercular Agents; Antibiotics, Antitubercular; Calcineurin Inhibitors; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Mycophenolic Acid; Antilymphocyte Serum; Cyclosporine; Cyclosporins
• Other Study ID Numbers: 2012.00; FHCRC-2012.00 (Other Identifier: FHCRC Protocol Number); CDR0000597623 (Registry Identifier: PDQ); T32CA009515 (U.S. NIH Grant/Contract)